



23 December 2022

**Clarification to ASX announcement of 23 December 2022 - Opyl completes Placement and launches Rights Issue**

**Opyl Limited (ASX:OPL)** refers to the "Opyl completes Placement and launches Rights Issue" announcement released with the ASX on 23 December 2022.

The Company wishes to correct the following statement:

*"The Placement Shares are intended to be issued under the Company's current capacity pursuant to ASX Listing Rule 7.1(8,157,808 Shares) and 7.1A (5,438,538 Shares)."*

This should state:

*The Placement Shares are intended to be issued under the Company's current capacity pursuant to ASX Listing Rule 7.1(8,157,808 Shares) and 7.1A (1,508,859 Shares).*

The Board has authorised this announcement for release to the ASX.

**- ENDS-**

For media and investor enquiries: [info@opyl.ai](mailto:info@opyl.ai)

For clinical trial recruitment enquiries: [info@opin.ai](mailto:info@opin.ai)

[www.opyl.ai](http://www.opyl.ai)

[www.opin.ai](http://www.opin.ai)

Opyl is a new generation Australian digital health company that applies artificial intelligence to improving clinical trials. Our platforms make clinical trials more efficient and easier to access, giving patients more options and saving medical researchers time and money.

Our key offering for biopharma, medtech, government and healthcare organisations:

- clinical trial recruitment solutions – Opin.ai
- clinical trial predictive analytics and protocol design – TrialKey
- deep social media insights and analysis – Social Insights

Follow Opyl on Twitter (@Opylai), LinkedIn and Facebook